Literature DB >> 2439544

Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes.

M E Medof, A Gottlieb, T Kinoshita, S Hall, R Silber, V Nussenzweig, W F Rosse.   

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) erythrocytes exhibit abnormalities in decay accelerating factor (DAF), acetylcholinesterase, and resistance to autologous C5b-9 attack. To investigate the nature of the lesion underlying PNH cells, we examined the relationship of these abnormalities to one another. Analyses of DAF in acetylcholinesterase-negative erythrocytes revealed that these two abnormalities involve functionally independent molecules, coincide precisely in the same cell populations, and are similarly expressed in PNH II and more complement-sensitive PNH III erythrocytes. The DAF and acetylcholinesterase deficiencies contrast with the C3b/C4b receptor (CR1) deficit, which is less profound and similarly distributed in complement-insensitive cell populations. Hemolytic studies showed that defective resistance to autologous C5b-9 attack is mediated by another mechanism. Whereas reconstitution of PNH II erythrocytes with DAF completely corrected their complement sensitivity, DAF reconstitution of PNH III erythrocytes restored their ability to circumvent C3b uptake but had no effect on their heightened susceptibility to reactive lysis. Assays of complement-insensitive (PNH I) erythrocytes surviving after reactive lysis disclosed partial DAF and acetylcholinesterase deficits. These findings indicate that the PNH lesion involves multiple membrane components and that PNH I erythrocytes are also abnormal.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2439544      PMCID: PMC442215          DOI: 10.1172/JCI113043

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  41 in total

1.  Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.

Authors:  D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

2.  Variations in the red cells in paroxysmal nocturnal haemoglobinuria.

Authors:  W F Rosse
Journal:  Br J Haematol       Date:  1973-03       Impact factor: 6.998

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Inhibition of complement by a substance isolated from human erythrocytes. II. Studies on the site and mechanism of action.

Authors:  E M Hoffmann
Journal:  Immunochemistry       Date:  1969-05

5.  Inhibition of complement by a substance isolated from human erythrocytes. I. Extraction from human erythrocyte stromata.

Authors:  E M Hoffman
Journal:  Immunochemistry       Date:  1969-05

6.  Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite.

Authors:  N Yoshida; R S Nussenzweig; P Potocnjak; V Nussenzweig; M Aikawa
Journal:  Science       Date:  1980-01-04       Impact factor: 47.728

7.  Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. I. The sensitivity of PNH red cells to lysis by complement and specific antibody.

Authors:  W F Rosse; J V Dacie
Journal:  J Clin Invest       Date:  1966-05       Impact factor: 14.808

8.  The reaction mechanism of human C5 in immune hemolysis.

Authors:  N R Cooper; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1970-10-01       Impact factor: 14.307

9.  Complement lysis of human erythrocytes. Differeing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9.

Authors:  C H Packman; S I Rosenfeld; D E Jenkins; P A Thiem; J P Leddy
Journal:  J Clin Invest       Date:  1979-08       Impact factor: 14.808

10.  Increased efficiency of binding of nascent C3b to the erythrocytes of chronic cold agglutinin disease.

Authors:  C J Parker; C M Soldato; M J Telen
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

View more
  24 in total

Review 1.  Paroxysmal nocturnal hemoglobinuria and glycosyl phosphatidylinositol anchored proteins that regulate complement.

Authors:  C J Parker
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

Review 2.  Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia.

Authors:  Amy E DeZern; Robert A Brodsky
Journal:  Hematol Oncol Clin North Am       Date:  2015-03-07       Impact factor: 3.722

3.  Normal polymorphic variations and transcription of the decay accelerating factor gene in paroxysmal nocturnal hemoglobinuria cells.

Authors:  H A Stafford; M L Tykocinski; D M Lublin; V M Holers; W F Rosse; J P Atkinson; M E Medof
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

4.  Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria.

Authors:  M H Holguin; L R Fredrick; N J Bernshaw; L A Wilcox; C J Parker
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

5.  Tears contain the complement regulator CD59 as well as decay-accelerating factor (DAF).

Authors:  E Cocuzzi; L B Szczotka; W G Brodbeck; D S Bardenstein; T Wei; M E Medof
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

Review 6.  Complement in cancer: untangling an intricate relationship.

Authors:  Edimara S Reis; Dimitrios C Mastellos; Daniel Ricklin; Alberto Mantovani; John D Lambris
Journal:  Nat Rev Immunol       Date:  2017-09-18       Impact factor: 53.106

Review 7.  Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.

Authors:  Dimitrios C Mastellos; Edimara S Reis; Despina Yancopoulou; Antonio M Risitano; John D Lambris
Journal:  Semin Hematol       Date:  2018-02-14       Impact factor: 3.851

8.  Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80).

Authors:  R S McHugh; S N Ahmed; Y C Wang; K W Sell; P Selvaraj
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

9.  Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis.

Authors:  Peter N Lalli; Michael G Strainic; Min Yang; Feng Lin; M Edward Medof; Peter S Heeger
Journal:  Blood       Date:  2008-06-20       Impact factor: 22.113

Review 10.  Infectious diseases associated with complement deficiencies.

Authors:  J E Figueroa; P Densen
Journal:  Clin Microbiol Rev       Date:  1991-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.